SOCS3 and osteosarcoma: Furthermore, the finding that simvastatin is capable of inducing SOCS-3 and CIS gene expression, shows the potential of the JAK/STAT pathway as a therapeutic target, reinforcing the efficacy of simvastatin as chemotherapeutic drug for the treatment of osteosarcoma.